The drug is an under-the-skin injection that women would use about 45 minutes before anticipated sexual activity. It is intended to increase desire in women who experience “low sexual desire that causes marked distress or interpersonal difficulty.”
The approval of Vyleesi is controversial, according to STAT. Critics claim that prescribing a drug to increase sexual desire reduces the complexity of human sexuality to a biological issue.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
